DE29910454U1 - Agents for the therapy of hyperphosphataemia - Google Patents

Agents for the therapy of hyperphosphataemia

Info

Publication number
DE29910454U1
DE29910454U1 DE29910454U DE29910454U DE29910454U1 DE 29910454 U1 DE29910454 U1 DE 29910454U1 DE 29910454 U DE29910454 U DE 29910454U DE 29910454 U DE29910454 U DE 29910454U DE 29910454 U1 DE29910454 U1 DE 29910454U1
Authority
DE
Germany
Prior art keywords
calcium
magnesium
composition according
salts
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE29910454U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitasyn GmbH
Original Assignee
Vitasyn GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitasyn GmbH filed Critical Vitasyn GmbH
Priority to DE29910454U priority Critical patent/DE29910454U1/en
Publication of DE29910454U1 publication Critical patent/DE29910454U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßt The description text was not recorded electronically  

Der Beschreibungstext wurde nicht elektronisch erfaßtThe description text was not recorded electronically

Claims (10)

1. Mittel zur Senkung der Hypercalcämie und der Hy­ permagnesämle bei der Anwendung calcium- oder magnesi­ umhaltiger Phosphatbinder zur Therapie von Hyperphos­ phatämie, gekennzeichnet durch eine Darreichungsform als teilbare Tabletten (10) zur gleichzeitigen Appli­ kation phosphatbindender, unter physiologischen Bedin­ gungen löslichen Calcium- und Magnesiumverbindungen in einem sich bei der Resorption im Intestinaltrakt wech­ selseitig behindernden Mol-Verhältnis.1. Means to reduce hypercalcemia and Hy permagnesämle when using calcium or magnesi containing phosphate binders for the therapy of hyperphosphataemia, characterized by a dosage form as dividable tablets ( 10 ) for the simultaneous application of phosphate-binding, under physiological conditions soluble calcium and Magnesium compounds in a molar ratio that interferes with each other during absorption in the intestinal tract. 2. Mittel zur gleichzeitigen Applikation phosphatbin­ dender Calcium- und Magnesiumverbindungen nach An­ spruch 1, gekennzeichnet durch ein Mol-Verhältnis Cal­ cium zu Magnesium von 1 zu 0,2 bis 1 zu 20.2. Means for simultaneous application of phosphate calcium and magnesium compounds according to An saying 1, characterized by a molar ratio Cal cium to magnesium from 1 to 0.2 to 1 to 20. 3. Mittel nach den Ansprüchen 1 und 2, dadurch ge­ kennzeichnet, daß die Darreichungsformen in Bruchril­ len (11) teilbare Filmtabletten (10) sind.3. Composition according to claims 1 and 2, characterized in that the dosage forms in Bruchril len ( 11 ) are divisible film-coated tablets ( 10 ). 4. Mittel nach den Ansprüchen 1 bis 3, dadurch ge­ kennzeichnet, daß die Darreichungsformen zusätzlich zu den Magnesium- und Calciumverbindungen weitere, phar­ mazeutischen Regeln entsprechende Hilfsstoffe enthal­ ten.4. Agent according to claims 1 to 3, characterized ge indicates that the dosage forms in addition to the magnesium and calcium compounds more, phar contain appropriate auxiliary substances according to pharmaceutical rules ten. 5. Mittel nach den Ansprüchen 1 bis 4, dadurch ge­ kennzeichnet, daß die Darreichungsformen (10) blut­ phosphatspiegelsenkende Applikationsmittel zweiwertige Calcium- und Magnesium-Ionen zur Bildung schwerlösli­ cher Phosphatverbindungen im Gastrointestinaltrakt nach den gleichzeitig ablaufenden Reaktionen
3Ca2+ + 2(PO4)2 = Ca3(PO4)
beziehungsweise
3Mg2+ + 2(PO4)3- = Mg3(PO4)2
enthalten.5. Composition according to claims 1 to 4, characterized in that the dosage forms ( 10 ) blood phosphate-lowering application agent divalent calcium and magnesium ions to form heavily soluble phosphate compounds in the gastrointestinal tract after the simultaneous reactions
3Ca 2+ + 2 (PO 4 ) 2 = Ca 3 (PO 4 )
respectively
3Mg 2+ + 2 (PO 4 ) 3- = Mg 3 (PO 4 ) 2
contain. 6. Mittel nach den Ansprüchen 1 bis 5, dadurch gekenn­ zeichnet, daß die Darreichungsformen (10) Calcium­ acetat, Calciumalginat, Calciumcarbonat, Calciumcitrat, Calciumfumarat, Calciumgluconat, Calciumglutamat, Cal­ ciumhydroxid, Calciumlactat, Calciummalate, Calcium­ phytat, Calciumsilicate, Calciumsuccinat, Calciumtar­ tat, die Calciumsalze von Aminosäuren, die Calciumsalze der Ketoanaloga von Aminosäuren oder die Calciumsalze von organischen Säuren, die im pflanzlichen, tierischen und menschlichen Stoffwechsel angetroffen werden und gleichzeitig Magnesiumacetat, Magnesiumalginat, Magne­ siumcarbonat, Magnesiumcitrat, Magnesiumfumarat, Magne­ siumgluconat, Magnesiumglutamat, Magnesiumhydroxid, Na­ gnesiumlactat, Magnesiummalate, Magnesiumphytat, Magne­ siumsilicate, Magnesiumsuccinat, Magnesiumtartat, die Magnesiumsalze von Aminosäuren, die Magnesiumsalze der Ketoanaloga von Aminosäuren oder die Magnesiumsalze von organischen Säuren, die im pflanzlichen, tierischen und menschlichen Stoffwechsel angetroffen werden, enthal­ ten.6. Composition according to claims 1 to 5, characterized in that the dosage forms ( 10 ) calcium acetate, calcium alginate, calcium carbonate, calcium citrate, calcium fumarate, calcium gluconate, calcium glutamate, calcium hydroxide, calcium lactate, calcium malate, calcium phytate, calcium silicate, calcium succinate, calcium tar tat, the calcium salts of amino acids, the calcium salts of the keto analogues of amino acids or the calcium salts of organic acids, which are found in plant, animal and human metabolism and at the same time magnesium acetate, magnesium alginate, magnesium carbonate, magnesium citrate, magnesium fumarate, magnesium gluconate, magnesium glutamate, magnesium hydroxide, Magnesium lactate, magnesium malate, magnesium phytate, magnesium silicate, magnesium succinate, magnesium tartate, the magnesium salts of amino acids, the magnesium salts of the keto analogues of amino acids or the magnesium salts of organic acids, which are found in plant, animal and human Metabolism can be found. 7. Mittel nach den Ansprüchen 1 bis 6, dadurch ge­ kennzeichnet, daß die Darreichungsformen (10) Calcium- Magnesiumdoppelsalze enthalten.7. Composition according to claims 1 to 6, characterized in that the dosage forms ( 10 ) contain calcium-magnesium double salts. 8. Mittel nach den Ansprüchen 1 bis 7, dadurch ge­ kennzeichnet, daß die Darreichungsformen (10) Calcium- Magnesiumphytat enthalten. 8. Composition according to claims 1 to 7, characterized in that the dosage forms ( 10 ) contain calcium magnesium phytate. 9. Mittel nach den Ansprüchen 1 bis 7, dadurch ge­ kennzeichnet, daß die Tablette (10) aus 400 mg bis 500 mg, vorzugsweise 435 mg Calciumacetat, entsprechend 110 mg Calcium und 200 mg bis 300 mg, vorzugsweise 235 mg Magnesiumcarbonat, entsprechend 60 mg Magnesium be­ steht.9. Composition according to claims 1 to 7, characterized in that the tablet ( 10 ) from 400 mg to 500 mg, preferably 435 mg calcium acetate, corresponding to 110 mg calcium and 200 mg to 300 mg, preferably 235 mg magnesium carbonate, corresponding to 60 mg of magnesium. 10. Mittel nach den Ansprüchen 1 bis 7, dadurch ge­ kennzeichnet, daß die Tablette (10) aus 2,0 bis 3,0, vorzugsweise 2,75 mmol Calciumacetat und 2,0 bis 3,0, 2,47 mmol vorzugsweise Magnesiumcarbonat besteht.10. Composition according to claims 1 to 7, characterized in that the tablet ( 10 ) from 2.0 to 3.0, preferably 2.75 mmol, calcium acetate and 2.0 to 3.0, 2.47 mmol, preferably magnesium carbonate consists.
DE29910454U 1999-06-10 1999-06-10 Agents for the therapy of hyperphosphataemia Expired - Lifetime DE29910454U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE29910454U DE29910454U1 (en) 1999-06-10 1999-06-10 Agents for the therapy of hyperphosphataemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE29910454U DE29910454U1 (en) 1999-06-10 1999-06-10 Agents for the therapy of hyperphosphataemia

Publications (1)

Publication Number Publication Date
DE29910454U1 true DE29910454U1 (en) 1999-09-23

Family

ID=8074845

Family Applications (1)

Application Number Title Priority Date Filing Date
DE29910454U Expired - Lifetime DE29910454U1 (en) 1999-06-10 1999-06-10 Agents for the therapy of hyperphosphataemia

Country Status (1)

Country Link
DE (1) DE29910454U1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008051572A1 (en) * 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Preparation of phosphate binders and phosphate binders prepared in this way
WO2010117370A1 (en) * 2009-04-10 2010-10-14 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
US8236358B1 (en) 2009-04-10 2012-08-07 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
WO2014140402A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S. L. Use of derivatives with c-o-p bonds in patients with renal failure
US9394318B2 (en) 2012-11-30 2016-07-19 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
EP2324835B1 (en) * 2008-08-06 2016-07-20 Universitat de les Illes Balears Composition of dialysis liquid comprising crystallisation inhibitor substances
US10010559B2 (en) 2013-03-15 2018-07-03 Laboratorios Sanifit, S.L. Use of derivatives containing C-O-P bonds in patients with kidney failure
DE102017126255A1 (en) * 2017-11-09 2019-05-09 Apafit UG (haftungsbeschränkt) Portioning unit with mineral salts as an additive for water, their use and procedures
US10973838B2 (en) 2018-10-11 2021-04-13 Sanifit Therapeutics S.A. IP and IP analogs dosage regimens for the treatment of ectopic calcifications

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324835B1 (en) * 2008-08-06 2016-07-20 Universitat de les Illes Balears Composition of dialysis liquid comprising crystallisation inhibitor substances
DE102008051572A1 (en) * 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Preparation of phosphate binders and phosphate binders prepared in this way
US9610267B2 (en) 2009-04-10 2017-04-04 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
WO2010117370A1 (en) * 2009-04-10 2010-10-14 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
US8236358B1 (en) 2009-04-10 2012-08-07 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
US8247000B2 (en) 2009-04-10 2012-08-21 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
AU2009344184B2 (en) * 2009-04-10 2016-05-12 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
US9339481B2 (en) 2009-04-10 2016-05-17 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
US9889157B2 (en) 2009-04-10 2018-02-13 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
US10150784B2 (en) 2012-11-30 2018-12-11 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
US9394318B2 (en) 2012-11-30 2016-07-19 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
WO2014140402A1 (en) * 2013-03-15 2014-09-18 Laboratoris Sanifit, S. L. Use of derivatives with c-o-p bonds in patients with renal failure
CN105611913A (en) * 2013-03-15 2016-05-25 莱博若特瑞斯萨尼菲特有限公司 Use of derivatives with C-O-P bonds in patients with renal failure
US10010559B2 (en) 2013-03-15 2018-07-03 Laboratorios Sanifit, S.L. Use of derivatives containing C-O-P bonds in patients with kidney failure
EP2974714A1 (en) * 2013-03-15 2016-01-20 Laboratorios Sanifit, S.L. Use of derivatives with c-o-p bonds in patients with renal failure
DE102017126255A1 (en) * 2017-11-09 2019-05-09 Apafit UG (haftungsbeschränkt) Portioning unit with mineral salts as an additive for water, their use and procedures
US10973838B2 (en) 2018-10-11 2021-04-13 Sanifit Therapeutics S.A. IP and IP analogs dosage regimens for the treatment of ectopic calcifications

Similar Documents

Publication Publication Date Title
DE69532031T2 (en) MEDIA CONTAINING THYROID HORMONES
DE69821553T2 (en) Granule preparation containing simethicone and granulated anhydrous calcium phosphate
DE69617659T4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SELECTED LANTHANCAR BONATE HYDRATES
DE69928819T2 (en) DIPHOSPHONIC ACID CONTAINING COMPOSITIONS
EP0437274B1 (en) Bicarbonate and calcium containing infusion and dialysis solution
DE29910454U1 (en) Agents for the therapy of hyperphosphataemia
DE2551280A1 (en) L-DOPA PREPARATION
DE2801098A1 (en) IRON COMPOSITION AND METHOD OF MANUFACTURING IT
RU97106555A (en) THERAPEUTIC COMBINATION OF VITAMIN AND CALCIUM IN A UNIFIED GALENE TABLET FORM, METHOD FOR ITS PRODUCTION AND ITS APPLICATION
DE19917705C1 (en) Agents for the therapy of hyperphosphataemia
US5432200A (en) Method for increasing urinary excretion of electrolytes
CA1314233C (en) Calcium supplements
US2877253A (en) Therapeutic iron complex
FI98193C (en) Method for the preparation of a magnesium additive for food, feed and medicines
EP0625355B1 (en) Tablet with improved bioavailability containing dichloromethylenedephosphonic acid as active ingredient
EP0380829A1 (en) Magnesium potassium citrate
EP0474040B1 (en) Efferescent powder component and process for its production
DE1767017B2 (en) Push-in capsule iron supplement
DE19528524C2 (en) Calcium-containing agent for intestinal phosphate binding and process for its preparation
DE3632334C2 (en)
EP0426098B1 (en) Phosphate binding agent for oral administration
DE3809625C2 (en)
DE2804691C2 (en)
EP0429157A2 (en) Dietary supplementation with potassium magnesium citrate
DE2512247A1 (en) Tablets contg. drying agents - for protection against moisture

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 19991028

R150 Term of protection extended to 6 years

Effective date: 20021204

R151 Term of protection extended to 8 years

Effective date: 20050915

R152 Term of protection extended to 10 years

Effective date: 20070919

R071 Expiry of right